Answers are grounded in this paper and cite their sources.
HBV is a major public health threat globally. Chronic HBV infection remains the leading cause of liver cirrhosis and HCC worldwide, and the disease burden is further exacerbated by social stigma.1 Despite the availability of effective vaccines since 1980s, there are still 257.5 (95% uncertainty interval, 216.6–316.4) million people living with chronic HBV infection in 2022.2 Among them, only 14% of the infected population was diagnosed, and only 8% (6.8 million) of the patients eligible for treatment were treated. Without preventing new infections, finding the missing millions with chronic infections, and linking them to care, HBV will continue to claim lives. Eliminating HBV as a public health threat by 2030, as aiming for a 90% reduction in incident infection and 65% reduction in mortality compared to the 2015 baseline, is an ambitious goal endorsed by the World Health Organization (WHO). The ambitious WHO targets are believed to be achievable if the coverage of infant vaccination with timely birth dose exceeds 90%, the diagnosis of people with chronic infection exceeds 90%, and more than 80% of diagnosed and eligible patients can receive appropriate evaluation and treatment.3 Achieving these targets requires a steadfast commitment and concerted efforts from both public and private sectors, with collaborations that span the entire spectrum of HBV control, including preventing transmission, identifying the undiagnosed, linking the infected to care with surveillance, and providing antiviral therapy to those meeting treatment criteria. Progress toward elimination has been made in several regions, but projections from current data found no countries on track to achieve all of the WHO goals by 2030.4 With the aim to better understand the status of HBV epidemiology, care gaps, elimination efforts, and emerging innovations, this special series was developed to bring together reputable experts in the field to provide vital updates and their insights on key topics. Understanding the disease burden and gaps along the care continuum is the critical first step. To this end, an opening review provides a global overview of progress made and the ground still to be covered to reach the elimination goals. Furthermore, authors from Africa, Asia, Europe, Central and South America, and North America are invited to provide region-specific analyses of the challenges and achievements against HBV in different parts of the world. Substantial barriers on the road toward HBV elimination can vary across regions, with priority areas unique in each region. The cornerstone for reducing the global HBV burden is the prevention of new infections. As such, the implementation of infant vaccination, the importance of birth dose, the use of immunoglobulins, and antiviral treatment to minimize the risk of vaccine failures are reviewed. For patients infected with HBV, HCC is the major cause of related mortality, making effective interventions to reduce this risk crucial. Therefore, a dedicated article discusses the pitfalls of current practice recommendations and the feasibility of proactive treatment strategies for reducing HCC risks. In addition to various tools currently available, the path to elimination will require innovation. Discovering novel biomarkers and developing accurate and inexpensive point-of-care tests can be instrumental in expanding access to care globally. A cure for HBV would replace lifelong treatment, remove stigma, and potentially decrease clinical complications further. Realization of the cure starts with understanding the mechanisms of viral persistence and challenges in eradicating the virus from the liver. Finally, the latest progress on the development of novel therapeutics for HBV is reviewed with cautious optimism for the future. Together, these articles outline key challenges and strategies from a global perspective and are also tailored to the unique regional contexts. They examine the gaps in the current care cascade and investigate innovations needed on the road to elimination. We hope this series serves as a reference and call to action for all those committed to ridding our world of HBV.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: